SLC5A1 and type 1 diabetes mellitus: 2) Blood Glucose Reduction: As an SGLT1/2 inhibitor, Sotagliflozin can more effectively lower blood glucose levels in patients with T1D compared to a placebo when used as an adjunctive therapy (8).